Director & 10% Owner Makes Substantial Post-IPO Purchase

summarizeSummary

Andrew T. Kaplan, a Director and 10% Owner, acquired over $134 million in Kailera Therapeutics common stock via an open market purchase at the IPO price, alongside a significant conversion of preferred shares.

check_boxKey Events

• Substantial Open Market Purchase

  Andrew T. Kaplan, a Director and 10% Owner, purchased 8,398,438 shares of common stock for $134,375,008 at $16.00 per share on April 20, 2026.

• Preferred Stock Conversion

  Kaplan also acquired 17,857,143 shares of common stock through the automatic conversion of Series B Preferred Stock upon the closing of the IPO.

• Significant Insider Accumulation

  The total value of shares acquired by Kaplan, including the open market purchase and preferred stock conversion, amounts to over $580 million.

• Post-IPO Confidence

  These transactions, occurring immediately after the company's IPO, signal strong insider confidence in Kailera Therapeutics' valuation and future.

auto_awesomeAnalysis

This Form 4 filing reveals a highly significant vote of confidence from a key insider, Andrew T. Kaplan, following Kailera Therapeutics' recent initial public offering. The open market purchase of over $134 million in common stock at the IPO price of $16.00 demonstrates strong conviction in the company's valuation and future prospects. This purchase represents a substantial portion of the company's market capitalization. Additionally, the automatic conversion of Series B Preferred Stock into common stock further consolidates his significant ownership stake. This insider activity, particularly the discretionary open market buy, is a strong positive signal for investors, especially coming so soon after the IPO.